Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM)

Blood (2023) 142 (Supplement 1): 533.

https://doi.org/10.1182/blood-2023-185737

Published: 2023

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2344–2346.

https://doi.org/10.1182/blood-2022-166826

Published: 2022

Journal Articles

Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial

Blood (2022) 140 (Supplement 1): 2098–2100.

https://doi.org/10.1182/blood-2022-165441

Published: 2022

Journal Articles

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Blood (2021) 138 (19): 1901–1905.

https://doi.org/10.1182/blood.2021012319

Published: 2021

Includes: Supplemental data

Journal Articles

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Blood (2021) 138 (Supplement 1): 544.

https://doi.org/10.1182/blood-2021-151557

Published: 2021

Journal Articles

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Blood (2021) 137 (1): 49–60.

https://doi.org/10.1182/blood.2020006731

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136181

Published: 2020

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Blood (2019) 134 (Supplement_1): 506.

https://doi.org/10.1182/blood-2019-123974

Published: 2019

Journal Articles

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 581.

https://doi.org/10.1182/blood-2019-127717

Published: 2019

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 1852.

https://doi.org/10.1182/blood-2019-128655

Published: 2019

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2019) 134 (Supplement_1): 781.

https://doi.org/10.1182/blood-2019-125204

Published: 2019

Journal Articles

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

Maria Cristina Pascual Izquierdo, PhD MD, Julio Del Rio-Garma, MD, Javier De La Rubia, Aurora Viejo, MD, Jesus Fernandez-Sojo, MD, Jesus Martin, MD, Xavier Solanich, MD, Faustino García-Candel, PhD MD, Luis Hernandez, MD, Marta Fernandez, MD, Ana Oliva, MD, Jose Maria Garcia-Gala, MD, Maria Eva Mingot-Castellano, PhD MD, Ines Gomez-Seguí, MD PhD, Rosa Goterris, MD, Michael Calviño, MD, María Luisa Antelo, MD PhD, Sol Sanchez, MD, Jose Antonio Moreno, MD, Cristina Amunarriz, MD, Jose Garcia-Arroba, MD, Carmen Fernandez, MD, Nieves Alonso, MD, Victoria Gonzalez, MD, Luisa Guerra, MD, M. Elena Moreno, MD, Moreno M. Dolores, MD, Gemma Moreno, MD, Melisa Daorta, MD, Esther Chica, MD, Rafael Del Orbe, MD PhD, Joan Cid, MD PhD, Margarita Berberana, MD, Carmen Ballester, MD, Sara Nistal Gil, MD, Julia Vidan, MD, Maite Calderon, MD, Consuelo Martinez Redondo, MD, Jose Carlos Hernandez, MD, Marina Gordillo, MD, Angel Salgado, Ramon Salinas, MD PhD

Blood (2019) 134 (Supplement_1): 4910.

https://doi.org/10.1182/blood-2019-123258

Published: 2019

Journal Articles

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

Blood (2019) 133 (25): 2664–2668.

https://doi.org/10.1182/blood.2019000671

Published: 2019

Journal Articles

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Blood (2018) 132 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2018-99-117431

Published: 2018

Journal Articles

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Blood (2018) 132 (Supplement 1): 112.

https://doi.org/10.1182/blood-2018-99-113312

Published: 2018

Journal Articles

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 474.

https://doi.org/10.1182/blood-2018-99-115050

Published: 2018

Journal Articles

Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 1943.

https://doi.org/10.1182/blood-2018-99-116604

Published: 2018

NARROW

Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM)

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only